Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver

Molecular Therapy

Volumn 3, Issue 1, 2001, Pages 28-35

  Tao, Nianjun ^a   Gao, Guang Ping ^b   Parr, Michael ^a   Johnston, Julie ^b   Baradet, Timothy ^b   Wilson, James M ^b   Barsoum, James ^a   Fawell, Stephen E ^a  

^a BIOGEN   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenovirus; Dose response; Gene therapy; Interferon ; Kupffer

Indexed keywords

BETA INTERFERON; DOXORUBICIN; LIPOSOME; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HELPER VIRUS; KUPFFER CELL; LIVER CELL; MOUSE; NONHUMAN; NONLINEAR SYSTEM; REPORTER GENE; TIME; TRANSGENE; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 0034980914     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0227     Document Type: Article

References (34)

1. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver
2. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
3. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes
4. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
5. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery
6. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice
7. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA41g
8. Sensitivity and reproducibility in adenoviral infectious titer determination
9. Early events in the interaction of adenoviruses with HeLa cells. I. Penetration of type 5 and intracellular release of the DNA genome
10. Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells
11. Antigens and structure of the adenovirus
12. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
13. Evaluation of adenoviral vectors for treatment of hemophilia A: Demonstration of an unexpected non-linear in vivo dose response
14. Interferons
15. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
16. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver
17. Adenovirus-mediated gene transfer into human hepatocytes: Analysis of the biochemical functionality of transduced cells
18. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ
19. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
20. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages
21. Accumulation of protein-coated liposomes in an extravascular site: Influence of increasing carrier circulation lifetimes
22. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade
23. RAG-1-deficient mice have no mature B and T lymphocytes
24. In vitro activation of murine Kupffer cells by lymphokines or endotoxins to lyse syngeneic tumor cells
25. Differential properties of organ-specific serum opsonins for liver and spleen macrophages
26. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan
27. Gene therapy on trial
28. Preferential activation of dendritic cells and macrophages in vivo accounts for adenoviral vector-induced acute phase inflammatory reaction
29. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
30. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
31. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
32. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
33. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
34. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation